Primary thrombophilia, also known as hereditary thrombophilia, is a group of genetic disorders characterized by an increased tendency to develop venous thromboembolism (VTE). This hypercoagulable state is the result of inherited mutations or deficiencies in genes that regulate the coagulation cascade. The most common manifestations of primary thrombophilia include activated protein C resistance (Factor V Leiden), the prothrombin G20210A mutation, and deficiencies in the natural anticoagulants protein C, protein S, or antithrombin III. Clinical consequences typically involve deep vein thrombosis (DVT) and pulmonary embolism (PE), often occurring at a young age, without clear provocative factors, or in unusual locations. Management involves anticoagulation for acute events and potentially long-term prophylaxis based on the severity of the thrombophilic state and the patient's individual risk factors for recurrence.
Specify the exact genetic mutation or deficiency identifying the primary thrombophilia status.
Example: Patient returns for management of known primary thrombophilia. Genetic testing confirmed heterozygous Factor V Leiden mutation (D68.51). Patient has a history of recurrent unprovoked deep vein thrombosis of the left popliteal vein. Management involves lifelong anticoagulation with Apixaban 5mg twice daily. No signs of active bleeding or complications. The condition is stable but requires chronic monitoring for recurrent VTE risk and medication adherence.
Billing Focus: Identify the specific mutation type such as Factor V Leiden, Prothrombin G20210A, or Protein S deficiency to support the highest level of specificity within the D68.5 subcategory.
Differentiate between primary genetic thrombophilia and secondary acquired thrombophilia.
Example: Evaluation of hypercoagulability following a right femoral DVT. Laboratory workup negative for Antiphospholipid Syndrome (D68.61) but positive for Prothrombin gene mutation (D68.52). Diagnosis confirmed as primary thrombophilia. Plan: Initiation of Enoxaparin bridge to Warfarin with a target INR of 2.0 to 3.0. This is a chronic condition requiring ongoing specialized hematology follow-up.
Billing Focus: Ensure documentation explicitly states primary or hereditary to justify D68.5 codes versus D68.6 for acquired conditions.
Document the history of venous thromboembolism VTE and its relationship to the thrombophilic state.
Example: 45-year-old male with primary thrombophilia due to Antithrombin III deficiency (D68.59). Patient has a documented history of bilateral pulmonary emboli and chronic venous hypertension of the lower extremities. Currently maintained on Rivaroxaban 20mg daily. No active acute VTE noted today. Risk of recurrence is high without adherence to the medication regimen.
Billing Focus: Link the primary thrombophilia code with any history codes (Z86.718) or current VTE codes (I82 series) to provide a complete clinical picture of the episode of care.
Clearly state the long-term management plan including specific anticoagulation therapy.
Example: Primary thrombophilia characterized by Protein C deficiency (D68.59). Patient is on chronic anticoagulation therapy with Warfarin. Prothrombin time and INR checked today (INR 2.4). Patient advised on dietary vitamin K consistency and bleeding precautions. Condition requires indefinite anticoagulation due to the high risk of catastrophic thrombotic events.
Billing Focus: Include the long-term use of anticoagulants (Z79.01) to support the ongoing management of the primary condition.
Include relevant negative findings and absence of complications to support medical necessity for monitoring.
Example: Follow-up for Primary Thrombophilia (D68.5). Patient is asymptomatic today with no lower extremity edema, shortness of breath, or chest pain. No evidence of easy bruising or mucosal bleeding on current Dabigatran 150mg BID. Continued monitoring of renal function is required to ensure safe dosing of the direct oral anticoagulant. Patient remains at high risk for recurrence but is currently stable.
Billing Focus: Documenting the lack of complications while emphasizing the high-risk status justifies continued high-complexity monitoring visits.
Typically used for follow-up of primary thrombophilia involving management of anticoagulant therapy and review of lab trends.
Appropriate for patients with primary thrombophilia experiencing recurrent life-threatening clots or major bleeding complications from therapy.
Initial consultation for a patient referred after a first VTE to work up potential genetic causes.
Confirmatory diagnostic test for primary thrombophilia (D68.51).
Confirmatory diagnostic test for primary thrombophilia (D68.52).
Used to diagnose Protein C deficiency, categorized under D68.59.
Used to diagnose Protein S deficiency, categorized under D68.59.
Used to identify hereditary Antithrombin III deficiency (D68.59).
Imaging used to monitor for new or recurrent DVT in patients with known primary thrombophilia.
Routine visit for an asymptomatic patient with known thrombophilia for simple medication refill or review of stable labs.
Essential monitoring for patients on Warfarin due to primary thrombophilia.
Used to monitor heparin therapy or screening for lupus anticoagulants.